PULMOZYME DEVELOPMENT MAY BE PROTOTYPE FOR OTHER BIOTECH PRODUCTS; GENENTECH DECLINED TO SKIP PHASE 111 OR RUSH PLA FILING; ROCHE FINANCIAL SECURITY HELPED
Executive Summary
Genentech's Pulmozyme (dornase alfa) will enter commercial distribution in North America in mid-January -- less than six years after the initial cloning of the human recombinant DNase protein in Genentech's laboratories in 1988.